After a PhII catastrophe wiped out a billion dollars in market cap, Seres is looking for a do-over
Last summer, shares of Seres Therapeutics $MCRB were shredded by a failed Phase II study for their lead microbiome drug program, wiping out a billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
